Get the Stockscreener App
1.22
0.83%
0.01
Pre-market:
1.22
Filana Therapeutics Inc stock is traded at $1.22, with a volume of 442.01K.
It is up +0.83% in the last 24 hours and up +3.39% over the past month.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
See More
Previous Close:
$1.21
Open:
$1.21
24h Volume:
442.01K
Relative Volume:
1.12
Market Cap:
$58.94M
Revenue:
-
Net Income/Loss:
$-77.90M
P/E Ratio:
-0.7565
EPS:
-1.6127
Net Cash Flow:
$-30.38M
1W Performance:
-14.08%
1M Performance:
+3.39%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.17
$1.2283
1-Week Range:
$1.17
$1.45
52-Week Range:
$1.16
$2.0901
Filana Therapeutics Inc Stock (FLNA) Company Profile
Name
Filana Therapeutics Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN
Compare FLNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FLNA
Filana Therapeutics Inc
|
1.22 | 58.45M | 0 | -77.90M | -30.38M | -1.6127 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Filana Therapeutics Inc Stock (FLNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Filana Therapeutics Inc Stock (FLNA) Latest News
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineEarnings Trend Analysis - newsline.com
Filana Therapeutics, Inc. 8-K Filing Details: Amended 2018 Omnibus Incentive Plan and Company Information (June 2026) – Minichart - Minichart
Filana Therapeutics Shareholders Back Board, Compensation Plans - TipRanks
Filana Therapeutics (FLNA) investors back directors, plan changes and auditor - Stock Titan
Filana Therapeutics (FLNA) Slips 4.6% as Biotech Sector Headwinds Test SupportConversion Trade - newsline.com
FLNA Should I Buy - Intellectia AI
FLNA Price Today: Filana Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Filana Therapeutics (FLNA) Surges Over 8%—Testing Key Resistance at $1.50Beta Neutral Pair - newsline.com
Filana Therapeutics (FLNA) Edges Higher as Stock Tests Key Resistance LevelTrend Following Picks - newsline.com
Filana Therapeutics (FLNA) Slips 4.5% as Stock Approaches Key Support LevelIV Rank - newsline.com
MSN Money - MSN
Data I/O And 2 Other Promising Penny Stocks To Watch - simplywall.st
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Stock RallyEarnings Surprise Stocks - The Legal Advocate
FLNA Q3 2025 Earnings: Narrower-Than-Expected Loss Propels Shares HigherSurprise Factor Analysis - The Legal Advocate
Filana Therapeutics (FLNA) Gains 6.38% as Biotech Momentum BuildsPCR Spike - newsline.com
FLNA Reinstated by Maxim Group -- Price Target Announced at $5.0 - GuruFocus
FLNA Reinstated by Maxim Group -- Price Target Announced at $5.00 - GuruFocus
Filana Therapeutics (FLNA) Posts Modest Gains Amid Broader Biotech ResilienceExpert Breakout Alerts - Newser
Filana Therapeutics (FLNA) Stock: Up +0.80%, Key Resistance at $1.32 2026-05-21IPO Entry Watch - The Legal Advocate
Filana Therapeutics 1Q Loss/Shr 21c >FLNA - Moomoo
FLNA SEC FilingsFilana Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Filana Therapeutics (NASDAQ: FLNA) trims Q1 2026 loss, pivots simufilam to TSC epilepsy - Stock Titan
Filana Therapeutics Releases Q1 2026 Financial Results and Business Update on May 7, 2026 - geneonline.com
Filana Therapeutics Reports Q1 2026 Financial Results and Business Update - The Manila Times
Cost cuts shrink Filana Therapeutics (NASDAQ: FLNA) Q1 2026 net loss - Stock Titan
Biotech with $86.6M cash says FDA hold keeps epilepsy trial on hold - Stock Titan
Cassava Sciences | 8-K: Current report - Moomoo
Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII - markets.businessinsider.com
At a Madrid epilepsy meeting, Filana detailed why it’s testing simufilam - Stock Titan
MSN - MSN
Filana Therapeutics Inc Stock (FLNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Filana Therapeutics Inc Stock (FLNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Nov 20 '25 |
Buy |
2.76 |
150,000 |
414,000 |
938,060 |
| Barry Richard | President & CEO |
Nov 19 '25 |
Buy |
2.75 |
73,385 |
201,809 |
788,060 |
| Cook Robert Christopher | Chief Operating & Legal Office |
Sep 30 '25 |
Buy |
2.91 |
13,725 |
39,940 |
13,725 |
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):